Matches in Nanopublications for { ?s ?p "[Small molecule inhibitors targeting the kinase activity of ALK have proven to be effective therapies in certain ALK-driven malignancies and one such inhibitor, crizotinib, is now approved for the treatment of EML4-ALK-driven, non-small cell lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- assertion description "[Small molecule inhibitors targeting the kinase activity of ALK have proven to be effective therapies in certain ALK-driven malignancies and one such inhibitor, crizotinib, is now approved for the treatment of EML4-ALK-driven, non-small cell lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP207257.RAFrEs1IqPXUzNo-T5XPDnDJqhIls841hELVqj0DslHxY130_assertion description "[Small molecule inhibitors targeting the kinase activity of ALK have proven to be effective therapies in certain ALK-driven malignancies and one such inhibitor, crizotinib, is now approved for the treatment of EML4-ALK-driven, non-small cell lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP207257.RAFrEs1IqPXUzNo-T5XPDnDJqhIls841hELVqj0DslHxY130_provenance.
- NP155501.RAMYBxInaiD7_uPFLkDMTK0gvvRegFe-FZG58_MsEbMdI130_assertion description "[Small molecule inhibitors targeting the kinase activity of ALK have proven to be effective therapies in certain ALK-driven malignancies and one such inhibitor, crizotinib, is now approved for the treatment of EML4-ALK-driven, non-small cell lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP155501.RAMYBxInaiD7_uPFLkDMTK0gvvRegFe-FZG58_MsEbMdI130_provenance.
- NP890464.RAZBZEd4K27ISVrgOupEZjfQ4wGmHgPAlW2ROMPU8cwrE130_assertion description "[Small molecule inhibitors targeting the kinase activity of ALK have proven to be effective therapies in certain ALK-driven malignancies and one such inhibitor, crizotinib, is now approved for the treatment of EML4-ALK-driven, non-small cell lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP890464.RAZBZEd4K27ISVrgOupEZjfQ4wGmHgPAlW2ROMPU8cwrE130_provenance.